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CASE REPORT
Essential tremor responsive to levetiracetam
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ÖZET
Esansiyel tremor, genel popülasyonda prevelansı % 0.4-
3.9 olan ve yaş ile artan en sık görülen hareket bozuk-
luğudur. Esansiyel tremorlu hastaların medikal tedavileri 
sıklıkla  yetersizdir.  Propranolol  ve  primidon  vakaların 
2/3’de ilk tercih tedavilerdir. Bu yazı, propranolol ve primi-
donu yanıtsızlık ve yan etkiler nedeni ile kesilen levetira-
setama iyi cevap veren sakatlayıcı esansiyel tremorlu 58 
yaşındaki bir erkek hastayı rapor etmektedir.
Antiepileptik ilaçlardan biri olan levetirasetam, esansiyel 
tremor tedavisinde daha fazla yararlı olabilmektedir.
Anahtar kelimeler: Esansiyel tremor, antikonvülzan ilaç, 
levetirasetam
ABSTRACT
Essential tremor is one of the most common movement 
disorders with a prevalence of 0.4% to 3.9% in the gener-
al population and increases with age. The medical treat-
ment available for patients with essential tremor is often 
inadequate. Propranolol and primidone are the first-line 
treatment options, improving in up to two thirds of cases. 
This article reports a satisfying response to levetiracetam 
with disabling essential tremor in a 58-year-old man whom 
propranolol as well as primidone had to be discontinued 
due to unresponsiveness and severe side effects. One of 
the antiepileptic drugs, levetiracetam, may be more use-
ful in the treatment of essential tremor. J Clin Exp Invest 
2012; 3(1): 108-110
Key words: Essential tremor, anticonvulsant drug, leve-
tiracetam
INTRODUCTION
Essential tremor (ET) is one of the most common 
late-life movement disorder characterized by pro-
gressive postural and kinetic tremor typically affect-
ing the hands, arms, head, voice, truck and leg.1 
Propranolol and primidone are the first-line treat-
ment options. However, these drugs are ineffective 
in approximately 25–55 % of ET patients and are of-
ten have severe and potentially threatening adverse 
effects especially in elderly. 
It is important to know the reality that no drug 
is yet available to eliminate tremor nevermore ad-
ditional safe and well-tolerated drugs for the treat-
ment of ET patients are promptly needed.2 This ar-
ticle displays a case of ET who is effectively treated 
with levetiracetam (LEV).
CASE
A 58-year-old right-handed man referred to the out-
patient clinic with a history of bilateral postural and 
kinetic tremor, which was first noted more than five 
years  ago  and  developed  gradually  deterioration 
over the years. There was no drug use, family his-
tory or condition causing this movement disorder. 
The state of cerebellar signs or symptoms, hyper-
thyroidism, alcoholism, peripheral neuropathy and 
anxiety were ruled out and diagnosed definite ET. 
In his medical history, he had hypertension and dia-
betes. Brain magnetic resonance imaging showed 
diffuse  cerebral  atrophy  and  mild  periventricular 
leuko-araiosis.
He was having difficulties in everyday activi-
ties like drinking, eating, dressing, writing, and other 
tasks requiring hand movements. Tremor severity 
was measured by using the Fahn-Tolosa-Marin clin-
ical rating scale and scored as 3 points (markedly) 
at the first clinical examination.3
Medication was started with propranolol, first 
with daily dosage of 40 mg/day and increased grad-
ually to 120 mg/day within four weeks. After three A. Milanlıoğlu et al. Essential tremor 109
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months follow-up, any improvement was acquired 
and even gradually worsened, finally added primi-
done 250 mg/day, but it had to be discontinued be-
cause  of  the  severe  and  threatening  side  effects 
like drowsiness, vertigo and unstable gait. After the 
ineffective  and  unwell-tolerated  treatment  options 
with propranolol and primidone, LEV was started 
and tolerated well, so the dosage was titrated from 
500 mg/day to 2000 mg/day within four weeks. Six 
months follow-up, it showed a continuing ameliorat-
ing effect on ET, providing comfort for making sim-
ple activities of daily living. Moreover the repeat of 
Fahn-Tolosa-Marin clinical rating scale was scored 
as 2 points (moderately abnormal) and no function-
al disabilities were reported anymore.
DISCUSSION
Antiepileptic drugs are extensively used to treat a 
wide range of neurological disorders than epilepsy, 
such as neuropathic pain, migraine and ET.4
Recently, various agents including topiramate, 
benzodiazepines, gabapentin, zonisamide and le-
vetiracetam that dramatically improve functions in 
ET patients have been documented in several tri-
als.5 In this case of 58-year-old man with ET, after 
inefficient and unwell-tolerated treatment with pro-
pranolol and primidone, LEV was found to be very 
effective. Additionally, the score of decline on Fahn-
Tolosa-Marin clinical rating scale during the course 
of ET treatment with LEV also proved the efficiency. 
We observed antitremor effect in our patient after 
taking 1000 mg/day so the dosage was gradually 
titrated  to  2000  mg/day  for  the  significant  effect. 
In literature, the maximum dose of LEV was 3000 
mg/day which was reached by patients who did not 
benefit from lower doses after one week treatment 
with 1000 mg and four weeks treatment with 2000 
mg/day.6
Levetiracetam  is  originally  used  as  a  broad-
spectrum antiepileptic drug. However, it has several 
potential mechanisms of action, which is thought to 
be the enhancement of GABAergic and a decrease 
in  glutamatergic  neurotransmission.7 To  date,  the 
definite  mechanism  of  action  of  LEV  in  reducing 
tremor is not clearly understood. It is suggested that 
Levetiracetam may possibly act via an influence on 
the increment of GABAergic activity and also the 
decline of glutamatergic neurotransmission and ex-
citotoxicity.
Levetiracetam is not only effective in ET but 
also it is useful for different types of tremor of neu-
rological disorders. The efficacy of LEV in holmes’, 
intention, cortical myoclonic tremor and tremor in 
multiple sclerosis seems to be promising in some 
case reports but needs to be investigated in larger 
patient groups.8,9
In  a  double-blind,  placebo  controlled  trial  of 
Bushara et al., the effect of single dose of 1000 mg 
LEV on essential tremor was investigated in 24 pa-
tients and they showed significant hand tremor re-
duction for at least 2 hours by using accelerometry 
and functional tests.10
On the contrary, the study of 15 patients diag-
nosed with ET during the treatment of 500-3000 mg/
day during a 5-week slowly titration phase displayed 
that the analysis of tremor rating scale revealed a 
statistically insignificant trend for all data.11
Further randomized and blinded studies with a 
larger cohort of patients and basic research must 
be performed in order to exactly elucidate the anti-
tremor effect of LEV.
Consequently,  this  case  demonstrates  that 
LEV can be alternative option in the treatment of 
patients diagnosed with ET whom propranolol and 
primidone had to be discontinued due to unrespon-
siveness and severe side effects.
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